Status:
UNKNOWN
RALPPS Venus ALPPS for Hepatocellular Carcinoma
Lead Sponsor:
Southwest Hospital, China
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Currently，the "ALPPS" (associating liver partition with portal vein ligation for staged hepatectomy) procedure which enables the rapid growth of the future liver remnant and extends surgical indicatio...
Eligibility Criteria
Inclusion
- An insufficient future liver remnant(FLR\<30% in normal hepatic function or FLR\<40% with hepatic cirrhosis or after chemotherapy）
- Liver function of Child-Pugh Class A or B.
- Liver Reserve Function：ICG-R15≤10％
- No evidence of coagulopathy: platelet count \> 50 × 109/L and a prolonged prothrombin time of \< 5 seconds.
Exclusion
- Patients met the inclusion criteria but declined to participate.
- Patients with severe portal hypertension, a history of esophageal variceal hemorrhage, severe hypersplenism syndrome, or refractory ascites.
- Main portal vein、inferior vena cava、common hepatic duct and hepatic vein have tumor thrombus.
- Extrahepatic or lymph node metastasis
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT02299843
Start Date
October 1 2014
End Date
December 1 2016
Last Update
December 2 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of hepatobiliary surgery,Southwest Hospital
Chongqing, Chongqing Municipality, China, 400038